ProShare Advisors’s ADC Therapeutics ADCT Stock Holding History

ProShare Advisors’s Portfolio ADCT Stock Details ADCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$15K	Sell	14,044 -755	-5%	-$2.2K	﹤0.01%	1906
2026 Q1	$55.5K	Sell	14,799 -928	-6%	-$3.66K	﹤0.01%	1773
2025 Q4	$55.5K	Buy	15,727 +3,339	+27%	+$13.5K	﹤0.01%	1945
2025 Q3	$49.6K	Sell	12,388 -2,467	-17%	-$7.78K	﹤0.01%	1934
2025 Q2	$39.8K	Sell	14,855 -2,750	-16%	-$5.79K	﹤0.01%	2023
2025 Q1	$24.8K	Sell	17,605 -5,296	-23%	-$9K	﹤0.01%	2023
2024 Q4	$45.6K	Buy	22,901 +7,535	+49%	+$19.7K	﹤0.01%	2191
2024 Q3	$48.4K	Buy	+15,366	New	+$48.5K	﹤0.01%	1983

Other funds holding ADCT

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

ProShare Advisors's ADCT Position: Q2 2026 in Review

ProShare Advisors reduced its ADC Therapeutics (ADCT) stake by 5.1% in Q2 2026, selling an estimated $2.2K and leaving 14,044 shares worth $15K. The position accounts for ﹤0.01% of the portfolio, ranked #1906.

ProShare Advisors first reported a position in ADCT in Q3 2024 and has held it in 8 quarters since. The position peaked at $55.5K in Q4 2025. 114 funds tracked by Wall St. Rank hold ADCT as of Q2 2026.

ProShare Advisors held 14,044 shares of ADC Therapeutics worth $15K as of Q2 2026.
ProShare Advisors sold 755 ADC Therapeutics shares in Q2 2026, an estimated $2.2K.
ADC Therapeutics made up ﹤0.01% of ProShare Advisors's portfolio in Q2 2026, its #1906 holding.
ProShare Advisors first reported a position in ADC Therapeutics in Q3 2024 and has held it in 8 quarters since.
ProShare Advisors's ADC Therapeutics position peaked at $55.5K in Q4 2025.
114 funds tracked by Wall St. Rank held ADC Therapeutics as of Q2 2026.

Based on ProShare Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.